AA
ALDX icon

ALPS Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

ALPS Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-43,803
Closed -$252K – 1027
2025
Q1 		$252K Sell
43,803
-4,352
-9% -$25.7K ﹤0.01% 947
2024
Q4 		$240K Buy
48,155
+2,619
+6% +$13.4K ﹤0.01% 958
2024
Q3 		$245K Sell
45,536
-790
-2% -$3.76K ﹤0.01% 970
2024
Q2 		$153K Buy
+46,326
New +$181K ﹤0.01% 958
2023
Q4 		– Sell
-43,250
Closed -$289K – 962
2023
Q3 		$289K Buy
43,250
+192
+0.4% +$1.43K ﹤0.01% 895
2023
Q2 		$361K Buy
43,058
+4,477
+12% +$44.1K ﹤0.01% 702
2023
Q1 		$383K Sell
38,581
-1,175
-3% -$8.3K ﹤0.01% 638
2022
Q4 		$277K Buy
39,756
+7,943
+25% +$45.4K ﹤0.01% 929
2022
Q3 		$170K Sell
31,813
-2,768
-8% -$16.6K ﹤0.01% 1014
2022
Q2 		$138K Sell
34,581
-25,125
-42% -$86.4K ﹤0.01% 1015
2022
Q1 		$265K Sell
59,706
-7,517
-11% -$29.9K ﹤0.01% 783
2021
Q4 		$269K Sell
67,223
-3,692
-5% -$28.2K ﹤0.01% 848
2021
Q3 		$623K Sell
70,915
-4,988
-7% -$45.8K 0.01% 473
2021
Q2 		$860K Buy
75,903
+5,676
+8% +$68.2K 0.01% 422
2021
Q1 		$834K Buy
70,227
+1,057
+2% +$12.2K 0.01% 421
2020
Q4 		$475K Buy
+69,170
New +$486K 0.01% 505

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ALPS Advisors's ALDX Position: Q2 2025 in Review

ALPS Advisors sold out of Aldeyra Therapeutics (ALDX) in Q2 2025, closing a stake of 43,803 shares — an estimated $252K sold.

ALPS Advisors first reported a position in ALDX in Q4 2020 and held it in 16 quarters. The position peaked at $860K in Q2 2021. 121 funds tracked by Wall St. Rank hold ALDX as of Q2 2025.

  • ALPS Advisors reported no remaining Aldeyra Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ALPS Advisors sold 43,803 Aldeyra Therapeutics shares in Q2 2025, an estimated $252K.
  • ALPS Advisors first reported a position in Aldeyra Therapeutics in Q4 2020 and held it in 16 quarters.
  • ALPS Advisors's Aldeyra Therapeutics position peaked at $860K in Q2 2021.
  • 121 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2025.

Based on ALPS Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.